Frequently asked questions about BPC-157 TB-500

Question

Accepted Answer

These are the most common BPC-157 TB-500 questions from search and research-community forums, answered from the published record. Where an answer makes a quantitative claim, it cites the study behind it. Where the record is silent — most importantly on the combination itself — the answer says so plainly. What is BPC-157 and TB-500? BPC-157 is a synthetic 15-amino-acid pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region (residues 17-23) of Thymosin Beta-4. The "Wolverine" blend pairs the two as a research-community tissue-repair stack . How does BPC-157 work compared to TB-500? BPC-157 supplies a local cytoprotective and pro-angiogenic signal: it up-regulates VEGFR2 with downstream Akt-eNOS signaling, modulates vasomotor tone via Src-Caveolin-1-eNOS, and sensitizes tendon fibroblasts through growth-hormone-receptor and FAK-paxillin signaling . TB-500 supplies an intracellular actin-sequestration signal — 1:1 G-actin binding via the LKKTETQ motif — that regulates cell migration . They act through complementary but largely non-overlapping pathways. Do BPC-157 and TB-500 act through the same pathway? No. BPC-157 acts on VEGFR2-Akt-eNOS, nitric-oxide/Src-Caveolin-1-eNOS, and growth-hormone-receptor signaling; TB-500 acts on the cytoskeleton by sequestering monomeric G-actin . The "synergy" rationale rests on these being complementary, non-overlapping mechanisms — it is a theoretical extrapolation, not a demonstrated combination finding. Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)? In preclinical models, yes, by separate routes. BPC-157 up-regulates VEGFR2 and promotes its internalization with downstream Akt-eNOS signaling (increased vessel density, faster blood-flow recovery in ischemic rat muscle) and modulates vasomotor tone via Src-Caveolin-1-eNOS ; Thymosin Beta-4 (TB-500's parent) promotes angiogenesis by endothelial migration . No controlled combination study has measured their combined angiogenic effect. What is the Wolverine peptide blend? A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed and marketed as a tissue-repair "stack." It is not a single chemical entity, has no CAS number or standardized ratio, and is not an approved product anywhere . What is the BPC-157 and TB-500 blend used for in research? Preclinical (mostly rodent) research on the two constituents covers tendon, ligament, muscle, and bone repair, wound and soft-tissue healing, cytoprotection, and angiogenesis . These are single-compound, animal-model findings; the blend itself has no controlled efficacy study. Why are BPC-157 and TB-500 combined (the Wolverine stack)? The rationale is complementary mechanisms: BPC-157's local cytoprotective and angiogenic signal (VEGFR2-Akt-eNOS) is paired with TB-500's cytoskeletal cell-migration signal, so the two are proposed to cover different stages of tissue repair . Critically, no head-to-head or combination study has defined a synergistic dose, ratio, or endpoint . Is there any study showing BPC-157 and TB-500 work better together (synergy)? No. No peer-reviewed study has defined a synergy ratio, dose, or endpoint for the two given together. A 2025 systematic review of BPC-157 — 36 studies, only 1 human, "no clinical safety data" — makes no mention of TB-500 or combination use . "Synergy" is an extrapolation from each peptide's separate mechanism. Are BPC-157 and TB-500 FDA approved or banned by WADA? Neither constituent is FDA-approved and the blend has no approved indication. FDA placed BPC-157 in 503A Category 2 (bulk substances that may present significant safety risks, not eligible for the compounding enforcement-discretion policy) and placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in the same category . Both are WADA-prohibited (BPC-157 under S0; TB-500 / Thymosin Beta-4 under prohibited peptide and growth-factor categories) . Are there human clinical trials on the BPC-157 + TB-500 combination? None. There are no controlled clinical trials of the combination for any indication. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies; "TB-500" human data are for full-length Thymosin Beta-4, not the heptapeptide. Recent reviews call BPC-157 investigational . Does the BPC-157 TB-500 blend help tendon and ligament injuries? In animal models, BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures, and at the cellular level enhanced tendon-fibroblast outgrowth, survival, and migration (FAK-paxillin signaling) and up-regulated the growth-hormone receptor . These are preclinical, single-compound results, not human or combination evidence. Does BPC-157 and TB-500 help muscle tears and recovery? The recovery rationale rests on animal-model, single-compound data: BPC-157's tendon-fibroblast outgrowth and growth-hormone-receptor effects , and the consolidated Thymosin Beta-4 review describing cell migration, anti-scarring, and angiogenic activity . No human combination recovery data exist. How does TB-500 work (actin / Thymosin Beta-4)? TB-500 is the Ac-LKKTETQ fragment of Thymosin Beta-4. X-ray crystallography of a gelsolin-domain-1–Thymosin-Beta-4 hybrid bound to actin established that Thymosin Beta-4 forms a 1:1 complex with monomeric G-actin and sequesters it by capping both ends, preventing polymerization — the cytoskeletal basis for its cell-migration and re-epithelialization role . What is the half-life of BPC-157 and TB-500? No validated human half-life exists for either constituent or the blend. BPC-157's elimination half-life was reported under 30 minutes in a rat/dog pharmacokinetic study; human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide . How do you reconstitute a BPC-157 / TB-500 blend (10mg)? Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed . This is research-handling context, not a human-use instruction. How often should you inject BPC-157 and TB-500? There is no validated injection schedule for the blend. Underlying rodent studies used a range of dosing — for example Thymosin Beta-4 at 150 µg twice weekly intraperitoneally for six months in one model ; community "loading then maintenance" protocols have no controlled-trial basis. Side Effects and Safety Signals in Research There is no controlled human safety dataset for the blend. A 2025 BPC-157 systematic review explicitly found "no clinical safety data" ; 2025-2026 reviews note that unapproved musculoskeletal peptides can carry potential for serious harm and operate largely outside regulatory oversight . Long-term human safety of the combination is unknown. TB-500 and the Tumor-Angiogenesis Question Thymosin Beta-4 has been implicated in tumor metastasis and angiogenesis in tumor models, so the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression; recent reviews stress that human safety data are scarce . This is a theoretical safety consideration, not a demonstrated cancer-causing effect of TB-500 in humans. BPC-157 vs TB-500: Two Distinct Compounds They are structurally unrelated. BPC-157 is a 15-amino-acid pentadecapeptide (~1419.5 Da) from a gastric-juice protein acting via VEGFR2/eNOS angiogenic and growth-hormone-receptor pathways ; TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ, ~889 Da) of Thymosin Beta-4 that sequesters G-actin to regulate cell migration . Different sequences, sizes, and mechanisms. Is Wolverine legal? The blend has no approved status anywhere, and neither constituent is an FDA-approved drug. Both BPC-157 and TB-500 currently sit in FDA 503A Category 2, outside FDA's enforcement-discretion policy for 503A compounding, and both are WADA-prohibited . See Wolverine legal status and FDA 503A category for the full picture. Can you get BPC-157 from a compounding pharmacy? BPC-157 is in FDA 503A Category 2 (effective with the September 29, 2023 update), so it is not within FDA's enforcement-discretion policy for 503A compounding, and routine compounding access is currently restricted while that status stands . BPC-157 is on the July 23-24, 2026 PCAC agenda as a substance being considered for the 503A Bulks List — a scheduled evaluation, not a listing decision . What is the FDA 503A status of Wolverine? The blend has no 503A status of its own; status attaches to each constituent. Both BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" are in 503A Category 2 effective with the September 29, 2023 update , and both appear on the July 2026 PCAC agenda as candidates under evaluation .